Search Articles

View query in Help articles search

Search Results (1 to 4 of 4 Results)

Download search results: CSV END BibTex RIS


Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Figure 5 C illustrates that within the realm of CVDs, “Embolism and Thrombosis” emerges as the most prevalent LV3 Me SH descriptor utilized in the literature, followed by “Hypertension” and “Heart Failure,” among others, in descending order of frequency. By comparing Figure 5 B and 5 C, we observe a less diverse distribution of the embedded Me SH terms.

Rene Markovič, Luka Ternar, Tim Trstenjak, Marko Marhl, Vladimir Grubelnik

Interact J Med Res 2024;13:e55699

Online Search Trends Influencing Anticoagulation in Patients With COVID-19: Observational Study

Online Search Trends Influencing Anticoagulation in Patients With COVID-19: Observational Study

This was soon followed by marked increases in clinical thrombosis, including deep vein thromboses, pulmonary emboli [1,2], and microthrombi in pulmonary vasculature in postmortem pathological studies [3]. Clinical debate ensued surrounding the best strategy to prevent and treat COVID-19–associated coagulopathy. By the middle of April 2020, an international position paper recommended the provision of adequate thromboprophylaxis in hospitalized patients with COVID-19 [4].

Amy P Worrall, Claire Kelly, Aine O'Neill, Murray O'Doherty, Eoin Kelleher, Anne Marie Cushen, Cora McNally, Samuel McConkey, Siobhan Glavey, Michelle Lavin, Eoghan de Barra

JMIR Form Res 2021;5(8):e21817

COVID-19 #StayAtHome Restrictions and Deep Vein Thrombosis: Case Report

COVID-19 #StayAtHome Restrictions and Deep Vein Thrombosis: Case Report

An otherwise completely healthy 84-year-old woman was admitted to the hospital due to deep vein thrombosis (DVT) in mid-April 2020. She had no pre-existing conditions, she was not taking any medication, and she did not have any cardiovascular risk factors apart from her age. Before the COVID-19 pandemic, the patient was very mobile for her age; she regularly went out for shopping and walks with her husband, and was active in her church group.

Edna Blum, Youssef S Abdelwahed, Eileen Spiess, Ursula Mueller-Werdan, David M Leistner, Adrian Rosada

Interact J Med Res 2021;10(1):e23443

The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

This will include (1) the assessment of aspirin prophylactic efficacy for all types of thrombotic events that patients with ESRD may develop, namely nonfatal stroke, nonfatal myocardial infarction, arteriovenous fistula thrombosis, and cardiac mortality, and (2) the assessment of aspirin-related major bleeding events using Thrombolysis in Myocardial Infarction (TIMI) criteria [17-19].

Tiago Monique Lemos Cerqueira, Armando Fartolino Guerrero, Clara Krystal Pérez Fermin, Ricardo Wang, Evelin Elfriede Balbino, Janis L Breeze, Paola Gonzalez Mego, Daniele Argentina Silva, Walid Ezzeldin Omer, Nathalie Monique Vandevelde

JMIR Res Protoc 2018;7(8):e10516